当前位置: 首页 > 期刊 > 《中外医学研究》 > 2015年第1期
编号:13122268
重组人凝血因子Ⅶa在难治性出血治疗的临床观察(3)
http://www.100md.com 2015年1月5日 《中外医学研究》 2015年第1期
     [3] Bowman L J.Use of Recombinant Actiyated factor Ⅷ concentrate to Control Postoperative Hemorrhage in Complex Cardiovascular Surgery[J].Ann Thorac Surg,2008,85(3):1669-1677.

    [4] Niles S E.Increased Mortality Associated With the Early Coagulopathy of Trauma in Combat Casualties[J].J Trauma,2008,64(1):1459-1465.

    [5] Romagnoli S,Bevilacqua S,Gelsomino S,et al.Small-dose recombinant activated factor Ⅶ(Novoseven) in cardiac surgecy[J].Anesth Analg,2006,102(5):1320-1326.

    [6] Welsh A.Guidelines for the use of recombinant activated factor Ⅶ in massive obstetric haemorrhage[J].Aust NZJ Obstet Gynaecol,2008,48(2):12-16.

    [7] Diprose P,Herbertson M J O,Shaughnessy D,et al.Activated recombinant factor Ⅶ after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery:randomized double-blind placebo-controlled pilot study[J].British Journal of Anasthesia,2005,95(5):596-602.

    [8] Mac Laren R,Weber L A,Brake H,et al.A multicenter assessment of recombinant factor Ⅶa off-label usage:clinical experiences and associated outcomes[J].Transfusion,2005,45(3):34-42.

    (收稿日期:2014-09-19) (编辑:程旭然), 百拇医药(丘文凤 罗伟文)
上一页1 2 3